{"organizations": [], "uuid": "5244d7ae9a3c7fb73589f967bc8f30372f0e77a7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180405.html", "section_title": "Archive News &amp; Video for Thursday, 05 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-btg-says-2017-18-results-hit-by-15/brief-btg-says-2017-18-results-hit-by-150-million-pound-impairment-charge-idUSFWN1RH0OT", "country": "US", "domain_rank": 408, "title": "BRIEF-BTG says 2017/18 results hit by 150 million pound impairment charge", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.167, "site_type": "news", "published": "2018-04-05T14:17:00.000+03:00", "replies_count": 0, "uuid": "5244d7ae9a3c7fb73589f967bc8f30372f0e77a7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-btg-says-2017-18-results-hit-by-15/brief-btg-says-2017-18-results-hit-by-150-million-pound-impairment-charge-idUSFWN1RH0OT", "ord_in_thread": 0, "title": "BRIEF-BTG says 2017/18 results hit by 150 million pound impairment charge", "locations": [], "entities": {"persons": [], "locations": [{"name": "london", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "btg plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 5 (Reuters) - BTG PLC:\n* BTG HAS DELIVERED A GOOD FINANCIAL PERFORMANCE FOR YEAR, WITH REVENUE IN LINE WITH EXPECTATIONS\n* VERY GOOD GROWTH IN INTERVENTIONAL MEDICINE PRODUCT SALES REFLECTS MID-TEENS CER 1 GROWTH IN ONCOLOGY AND VASCULAR PORTFOLIOS, WHICH TOGETHER REPRESENT >90% OF REVENUE IN THIS BUSINES\n* LOWER SALES OF PNEUMRX ® COILS REFLECT THAT MARKET DEVELOPMENT, INCLUDING SECURING APPROPRIATE LEVELS OF REIMBURSEMENT, IS TAKING LONGER THAN EXPECTED\n* WE DO NOT EXPECT MATERIAL REVENUES FROM THIS PRODUCT OVER NEXT TWO YEARS\n* WE HAVE THEREFORE REASSESSED FAIR VALUE OF THIS ASSET, AND OUR FINANCIAL RESULTS FOR 2017/18 WILL INCLUDE AN IMPAIRMENT CHARGE OF APPROXIMATELY £150M\n* IN ADDITION, OUR 2018/19 RESULTS WILL INCLUDE A ONE-OFF RESTRUCTURING CHARGE OF UP TO £10M Source text for Eikon: Further company coverage: (London newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-05T14:17:00.000+03:00", "crawled": "2018-04-06T21:59:11.000+03:00", "highlightTitle": ""}